1 Verbalis J, "Vaptans for the treatment of hyponatremia: How who when and why" 6 : 199-209, 2007
2 Koshimizu T, "V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity" 103 : 7807-7812, 2006
3 Schrier R, "Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia" 355 : 2099-2112, 2006
4 Sterns R, "The treatment of hyponatremia" 29 : 282-299, 2009
5 Decaux G, "The syndrome of inappropriate secretion of antidiuretic hormone (SIADH)" 29 (29): 239-256, 2009
6 Berl T, "Saltwater investigoators. Oral tolvaptan is safe and effective in chronic hyponatremia" 21 : 705-712, 2010
7 Nedvetsky P, "Regulation of aquaporin-2 trafficking" 190 : 133-157, 2009
8 Palmer B, "Pathogenesis of ascites and renal salt retention in cirrhosis" 47 : 183-202, 1999
9 Waikar S, "Mortality after Hospitalization with Mild, Moderate, and Severe Hyponatremia" 857 : 857-865, 2009
10 Kengne F, "Mild hyponatremia and risk of fracture in the ambulatory elderly" 101 : 583-588, 2008
1 Verbalis J, "Vaptans for the treatment of hyponatremia: How who when and why" 6 : 199-209, 2007
2 Koshimizu T, "V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity" 103 : 7807-7812, 2006
3 Schrier R, "Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia" 355 : 2099-2112, 2006
4 Sterns R, "The treatment of hyponatremia" 29 : 282-299, 2009
5 Decaux G, "The syndrome of inappropriate secretion of antidiuretic hormone (SIADH)" 29 (29): 239-256, 2009
6 Berl T, "Saltwater investigoators. Oral tolvaptan is safe and effective in chronic hyponatremia" 21 : 705-712, 2010
7 Nedvetsky P, "Regulation of aquaporin-2 trafficking" 190 : 133-157, 2009
8 Palmer B, "Pathogenesis of ascites and renal salt retention in cirrhosis" 47 : 183-202, 1999
9 Waikar S, "Mortality after Hospitalization with Mild, Moderate, and Severe Hyponatremia" 857 : 857-865, 2009
10 Kengne F, "Mild hyponatremia and risk of fracture in the ambulatory elderly" 101 : 583-588, 2008
11 Palmer BF, "Integrated response to abnormalities in tonicity. In Clinical Disturbances of Water Metabolism" Raven Press Ltd 273-295, 1993
12 Wald R, "Impact of Hospital-Associated Hyponatremia on Selected Outcomes" 170 (170): 294-302, 2010
13 Verbalis J, "Hyponatremia- Induced Osteoporosis" 999 : 1-37, 2009
14 Palmer BF, "Hyponatremia in the intensive care unit" 29 : 257-270, 2009
15 Kinsella S, "Hyponatremia Independent of Osteoporosis is Associated with Fracture Occurrence" 5 : 275-280, 2010
16 Adrogue H, "Hyponatremia" 342 : 1581-1589, 2000
17 Chen S, "Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists" 3 : 82-95, 2007
18 Ghali J, "Conivaptan and its role in the treatment of hyponatremia" 3 : 253-268, 2009
19 Palmer BF, "Causes and management of hyponatremia" 37 : 1694-1702, 2003
20 Zeltser D, "Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia" 27 : 447-457, 2007
국립중앙도서관 "우편 복사 서비스"로 연결 됩니다.
KISS
